Clinical characteristics of all PMBCL patients (N = 159)
| Clinical feature . | Data . |
|---|---|
| Median age, y | 36 (range, 19-84) |
| Females | 91 (57) |
| Bulky (≥10 cm) | 112 (70) |
| B symptoms | 68 (43) |
| PS ≥ 2* | 64 (40) |
| Elevated LDH† | 115 (72) |
| LDH > 2× ULN‡ | 37 (24) |
| Extranodal sites > 1 | 61 (38) |
| Extranodal sites > 2 | 29 (18) |
| Stage I/II disease§ | 99 (62) |
| Extranodal sites | |
| Pleural and/or pericardial effusion | 65 (41) |
| Lung | 44 (28) |
| Bone | 11 (7) |
| Kidney/adrenal | 10 (6) |
| IPI¶ | |
| 0/1 factors | 58 (36) |
| 2/3 factors | 74 (47) |
| 4/5 factors | 22 (14) |
| RT in RT era (n = 50) | 39 (78) |
| RT in PET era (n = 109) | 31 (28) |
| Median follow-up, y | 7.8 (range, 0.6-17.8) |
| Clinical feature . | Data . |
|---|---|
| Median age, y | 36 (range, 19-84) |
| Females | 91 (57) |
| Bulky (≥10 cm) | 112 (70) |
| B symptoms | 68 (43) |
| PS ≥ 2* | 64 (40) |
| Elevated LDH† | 115 (72) |
| LDH > 2× ULN‡ | 37 (24) |
| Extranodal sites > 1 | 61 (38) |
| Extranodal sites > 2 | 29 (18) |
| Stage I/II disease§ | 99 (62) |
| Extranodal sites | |
| Pleural and/or pericardial effusion | 65 (41) |
| Lung | 44 (28) |
| Bone | 11 (7) |
| Kidney/adrenal | 10 (6) |
| IPI¶ | |
| 0/1 factors | 58 (36) |
| 2/3 factors | 74 (47) |
| 4/5 factors | 22 (14) |
| RT in RT era (n = 50) | 39 (78) |
| RT in PET era (n = 109) | 31 (28) |
| Median follow-up, y | 7.8 (range, 0.6-17.8) |
Unless otherwise noted, data are n (%).
IPI, International Prognostic Index; PS, performance status; ULN, upper limit of normal.
PS > 1 missing in 1 patient.
LDH missing in 5 patients (3%).
LDH > 2× ULN missing in 6 patients (4%). For 1 patient, LDH was elevated, but the absolute value is not known.
Stage III (n = 13); stage IV (n = 47).
IPI missing in 5 patients (3%).